$287.65
Value $509B
ABBV and PTGX stock compared: price, dividend, valuation and results, from SEC filings.
$287.65
Value $509B
$124.62
Value $8.0B
AbbVie (ABBV) has a market value of $509B and Protagonist Therapeutics (PTGX) $8.0B. Over the last year, with dividends, ABBV moved +26.9% and PTGX +47.0%. The P/E is 49.4 for ABBV and 23.2 for PTGX. Dividend yield: ABBV 2.41%, PTGX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABBV$509B
PTGX$8.0B
ABBV is 64 times PTGX
Revenue, 12 months
ABBV$66.0B
PTGX$552M
ABBV is 120 times PTGX
Net income, 12 months
ABBV$10.3B
PTGX$342M
ABBV is 30 times PTGX
Operating margin
ABBV32.2%
PTGX58.6%
26.4 points apart
ROIC
ABBV25.7%
PTGX33.2%
7.5 points apart
P/E
ABBV49.4
PTGX23.2
ABBV is 2.1 times PTGX
Dividend yield
ABBV2.4%
PTGX0.0%
2.4 points apart
5-year return
ABBV+193.8%
PTGX+242.2%
48.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABBV+193.8%
PTGX+242.2%
| Period | ABBVWith dividends | PTGXWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +26.9%Price +23.2% | +47.0%Price +47.0% |
| 3 years since November 17, 2023 | +130.6%+32.1% a yearPrice +108.5% | +641.3%+95.0% a yearPrice +641.3% |
| 5 years since November 17, 2021 | +193.8%+24.1% a yearPrice +145.8% | +242.2%+27.9% a yearPrice +242.2% |
| 10 years since November 18, 2016 | +616.4%+21.8% a yearPrice +376.5% | +395.9%+17.4% a yearPrice +395.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABBVAbbViePTGXProtagonist Therapeutics
| Price | $287.65 | $124.62 |
|---|---|---|
| Market value | $509B | $8.0B |
| Enterprise value (EV) | $579B | $7.2B |
| P/E | 49.4 | 23.2 |
| P/E, 5-year median | 57.0 | – |
| P/B | – | 7.3 |
| EV/EBIT | 27.3 | 22.1 |
| Free cash flow yield | 3.7% | 1.4% |
| Revenue, 12 months | $66.0B | $552M |
|---|---|---|
| Net income, 12 months | $10.3B | $342M |
| Free cash flow, 12 months | $18.9B | $109M |
| Earnings per share, 12 months | $5.81 | $5.36 |
| Revenue growth, year on year | 8.6% | -89.4% |
| Revenue growth a year, past | +5.9%over 5 years | +10.0%over 5 years |
| EPS growth a year, past | -2.8%over 5 years | – |
| Gross margin | 73.7% | – |
|---|---|---|
| Operating margin | 32.2% | 58.6% |
| Net margin | 15.7% | 62.0% |
| ROIC | 25.7% | 33.2% |
| ROE | – | 44.5% |
| Cash | $10.8B | $800M |
|---|---|---|
| Total debt | $80.9B | $8.6M |
| Net debt / EBITDA | 3.2 | -2.5 |
| Interest cover | 7.1× | – |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $6.92 | – |
| Dividend growth a year, past | +6.6%over 5 years | – |
| Buyback yield | 0.2% | – |
| Shareholder yield | 2.6% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, AbbVie ($509B) is about 64.0 times Protagonist Therapeutics ($8.0B), at today's prices.
Since November 18, 2016, ABBV's price moved +376.5% and PTGX's +395.9%. With dividends: ABBV +616.4% (+21.8% a year), PTGX +395.9% (+17.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for AbbVie and none for Protagonist Therapeutics. Over the last twelve months they paid $6.92 and – per share.
At today's price, the P/E is 49.4 for ABBV and 23.2 for PTGX. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 15.7% for AbbVie and 62.0% for Protagonist Therapeutics, and the operating margin 32.2% and 58.6%. Revenue was $66.0B and $552M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.